Anixa Biosciences Inc (ANIX)
3.57
+0.10
(+2.88%)
USD |
NASDAQ |
Nov 05, 16:00
3.57
0.00 (0.00%)
After-Hours: 20:00
Anixa Biosciences Enterprise Value: 89.84M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 89.84M |
| November 01, 2024 | 95.95M |
| October 31, 2024 | 90.80M |
| October 30, 2024 | 93.70M |
| October 29, 2024 | 105.28M |
| October 28, 2024 | 105.93M |
| October 25, 2024 | 82.76M |
| October 24, 2024 | 79.54M |
| October 23, 2024 | 79.86M |
| October 22, 2024 | 75.68M |
| October 21, 2024 | 76.64M |
| October 18, 2024 | 75.04M |
| October 17, 2024 | 74.39M |
| October 16, 2024 | 76.64M |
| October 15, 2024 | 75.68M |
| October 14, 2024 | 76.32M |
| October 11, 2024 | 75.04M |
| October 10, 2024 | 75.04M |
| October 09, 2024 | 76.64M |
| October 08, 2024 | 77.29M |
| October 07, 2024 | 78.90M |
| October 04, 2024 | 79.54M |
| October 03, 2024 | 79.54M |
| October 02, 2024 | 79.86M |
| October 01, 2024 | 79.54M |
| Date | Value |
|---|---|
| September 30, 2024 | 79.54M |
| September 27, 2024 | 80.83M |
| September 26, 2024 | 80.51M |
| September 25, 2024 | 79.54M |
| September 24, 2024 | 86.94M |
| September 23, 2024 | 82.11M |
| September 20, 2024 | 90.16M |
| September 19, 2024 | 88.23M |
| September 18, 2024 | 89.19M |
| September 17, 2024 | 88.87M |
| September 16, 2024 | 84.37M |
| September 13, 2024 | 85.98M |
| September 12, 2024 | 85.01M |
| September 11, 2024 | 77.61M |
| September 10, 2024 | 78.25M |
| September 09, 2024 | 80.18M |
| September 06, 2024 | 81.47M |
| September 05, 2024 | 86.19M |
| September 04, 2024 | 89.72M |
| September 03, 2024 | 82.01M |
| August 30, 2024 | 85.54M |
| August 29, 2024 | 84.90M |
| August 28, 2024 | 83.94M |
| August 27, 2024 | 85.87M |
| August 26, 2024 | 86.83M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
22.22M
Minimum
Mar 27 2020
176.17M
Maximum
Mar 17 2021
79.60M
Average
77.53M
Median
Enterprise Value Benchmarks
| Annovis Bio Inc | 109.96M |
| Akero Therapeutics Inc | 1.499B |
| ACADIA Pharmaceuticals Inc | 1.924B |
| Amicus Therapeutics Inc | 3.492B |
| Intra-Cellular Therapies Inc | 8.129B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.277M |
| Total Expenses (Quarterly) | 3.592M |
| EPS Diluted (Quarterly) | -0.10 |
| Earnings Yield | -10.92% |
| Normalized Earnings Yield | -10.08 |